SK18062002A3 - Pevné orálne farmaceutické kompozície obsahujúce valsartan - Google Patents

Pevné orálne farmaceutické kompozície obsahujúce valsartan Download PDF

Info

Publication number
SK18062002A3
SK18062002A3 SK1806-2002A SK18062002A SK18062002A3 SK 18062002 A3 SK18062002 A3 SK 18062002A3 SK 18062002 A SK18062002 A SK 18062002A SK 18062002 A3 SK18062002 A3 SK 18062002A3
Authority
SK
Slovakia
Prior art keywords
valsartan
pharmaceutically acceptable
solid oral
composition
hydrate
Prior art date
Application number
SK1806-2002A
Other languages
English (en)
Slovak (sk)
Inventor
Sabina Maria Ganter
Robert Frank Wagner
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SK18062002A3 publication Critical patent/SK18062002A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SK1806-2002A 2000-06-22 2001-06-20 Pevné orálne farmaceutické kompozície obsahujúce valsartan SK18062002A3 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59968700A 2000-06-22 2000-06-22
PCT/EP2001/006983 WO2001097805A2 (en) 2000-06-22 2001-06-20 Solid valsartan pharmaceutical compositions

Publications (1)

Publication Number Publication Date
SK18062002A3 true SK18062002A3 (sk) 2003-07-01

Family

ID=24400655

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1806-2002A SK18062002A3 (sk) 2000-06-22 2001-06-20 Pevné orálne farmaceutické kompozície obsahujúce valsartan

Country Status (21)

Country Link
EP (2) EP1296677A2 (zh)
JP (3) JP2003535895A (zh)
KR (2) KR100659644B1 (zh)
CN (2) CN100450478C (zh)
AU (2) AU8576801A (zh)
BR (1) BR0111868A (zh)
CA (1) CA2411882C (zh)
CZ (1) CZ20024180A3 (zh)
EC (1) ECSP024389A (zh)
HK (2) HK1052868A1 (zh)
HU (1) HUP0301390A3 (zh)
IL (2) IL153428A0 (zh)
MX (1) MXPA02012683A (zh)
NO (1) NO20026123L (zh)
NZ (2) NZ540748A (zh)
PL (1) PL358290A1 (zh)
RU (1) RU2333757C2 (zh)
SG (1) SG162605A1 (zh)
SK (1) SK18062002A3 (zh)
WO (1) WO2001097805A2 (zh)
ZA (1) ZA200210359B (zh)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200200764T2 (tr) * 1998-12-23 2002-07-22 Novartis Ag At-1 veya at-2 reseptörlerindeki artışın neden olduğu hastalıkların tedavisi için at-1 reseptör antagonisti veya at-2 reseptör modülatörünün kullanımı
MXPA04006917A (es) * 2002-01-17 2004-12-06 Novartis Ag Composiciones farmaceuticas que comprenden inhibidores de valsartan y endopeptidasa neutra.
US7468390B2 (en) 2002-01-17 2008-12-23 Novartis Ag Methods of treatment and pharmaceutical composition
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
TWI299663B (en) * 2002-05-14 2008-08-11 Novartis Ag Methods of treatment
WO2005013964A1 (ja) 2003-08-08 2005-02-17 Ajinomoto Co., Inc. ナテグリニド含有製剤
WO2006021443A2 (en) * 2004-08-26 2006-03-02 Novartis Ag Composition comprising an at1 receptor blocker and a macrolide t-cell immunomodulator
CA2592091A1 (en) 2004-12-24 2006-06-29 Krka, D.D., Novo Mesto Solid pharmaceutical composition comprising valsartan
JP2009001520A (ja) * 2007-06-21 2009-01-08 Kowa Co ジフェンヒドラミン含有固形製剤
RU2487710C2 (ru) 2007-10-09 2013-07-20 Новартис Аг Фармацевтическая композиция валсартана
WO2009059605A1 (en) * 2007-11-08 2009-05-14 University Of Copenhagen Small scale solid state screening
EP2067470A1 (en) * 2007-12-03 2009-06-10 Laboratorios Lesvi, S.L. Pharmaceutical compositions containing valsartan and process for its preparation
WO2011102702A2 (en) 2010-02-16 2011-08-25 Krka, D. D., Novo Mesto Process for the preparation of oral solid dosage forms comprising valsartan
CN102362865B (zh) * 2011-10-28 2013-06-26 山东司邦得制药有限公司 一种含有盐酸贝尼地平和缬沙坦的复方制剂及其应用
WO2013098576A1 (en) 2011-12-31 2013-07-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Immediate release pharmaceutical composition of valsartan
WO2013098578A1 (en) 2011-12-31 2013-07-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Immediate release pharmaceutical composition of valsartan hydrochlorothiazide
CN103599084B (zh) * 2013-11-22 2018-10-30 威海迪素制药有限公司 一种降压组合物
CN112807286A (zh) * 2021-01-20 2021-05-18 海南皇隆制药股份有限公司 一种缬沙坦分散片制备方法和缬沙坦分散片
CN112826806A (zh) * 2021-01-20 2021-05-25 海南皇隆制药股份有限公司 一种缬沙坦片制备方法和缬沙坦片
EP4295839A1 (en) 2022-06-20 2023-12-27 KRKA, d.d., Novo mesto Combination of valsartan and indapamide

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122010000024I1 (de) * 1990-02-19 2010-07-08 Novartis Ag Acylverbindungen
AU1850695A (en) * 1994-03-17 1995-10-03 Novartis Ag Treatment of diabetic nephropathy with valsartan
DE69624253T2 (de) * 1995-10-06 2003-08-07 Novartis Ag Ati-rezeptorantagonisten zur verhinderung und behandlung des postischemischen nervenversagens und zum schutze ischemischer nieren
JP4369994B2 (ja) * 1996-02-29 2009-11-25 ノバルティス アクチエンゲゼルシャフト アポトーシスの刺激のためのａｔ▲下１▼レセプターアンタゴニスト
JP3391801B2 (ja) * 1996-05-20 2003-03-31 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 向上した生物学的利用性を有する抗菌性組成物
GB9613470D0 (en) 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
US6541669B1 (en) * 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
SE9802973D0 (sv) * 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
TR200200764T2 (tr) * 1998-12-23 2002-07-22 Novartis Ag At-1 veya at-2 reseptörlerindeki artışın neden olduğu hastalıkların tedavisi için at-1 reseptör antagonisti veya at-2 reseptör modülatörünün kullanımı
KR20020089433A (ko) * 2000-04-12 2002-11-29 노파르티스 아게 유기화합물의 조합

Also Published As

Publication number Publication date
SG162605A1 (en) 2010-07-29
RU2333757C2 (ru) 2008-09-20
NO20026123D0 (no) 2002-12-19
HK1052868A1 (zh) 2003-10-03
CA2411882C (en) 2011-09-06
CN100450478C (zh) 2009-01-14
ECSP024389A (es) 2003-02-06
AU2001285768B2 (en) 2005-03-10
HUP0301390A3 (en) 2005-04-28
EP2072049A3 (en) 2009-12-30
CN1221256C (zh) 2005-10-05
CN1679551A (zh) 2005-10-12
WO2001097805A2 (en) 2001-12-27
CA2411882A1 (en) 2001-12-27
CN1437469A (zh) 2003-08-20
EP2072049A2 (en) 2009-06-24
ZA200210359B (en) 2003-11-13
EP1296677A2 (en) 2003-04-02
NO20026123L (no) 2003-02-18
KR20030019450A (ko) 2003-03-06
HK1083452A1 (en) 2006-07-07
PL358290A1 (en) 2004-08-09
CZ20024180A3 (cs) 2003-04-16
JP2007091758A (ja) 2007-04-12
BR0111868A (pt) 2003-07-01
JP2012211200A (ja) 2012-11-01
JP2003535895A (ja) 2003-12-02
NZ522953A (en) 2005-10-28
KR100525341B1 (ko) 2005-11-02
MXPA02012683A (es) 2003-04-25
NZ540748A (en) 2007-04-27
KR20050085978A (ko) 2005-08-29
WO2001097805A3 (en) 2002-08-29
IL153428A (en) 2013-12-31
KR100659644B1 (ko) 2006-12-21
IL153428A0 (en) 2003-07-06
AU8576801A (en) 2002-01-02
HUP0301390A2 (hu) 2003-11-28

Similar Documents

Publication Publication Date Title
KR100792389B1 (ko) 발사르탄의 고형 경구제형
SK18062002A3 (sk) Pevné orálne farmaceutické kompozície obsahujúce valsartan
US20100267789A1 (en) Tablet formulations comprising valsartan
AU2001285768A1 (en) Solid valsartan pharmaceutical compositions
AU2005200815B2 (en) Solid valsartan pharmaceutical compositions

Legal Events

Date Code Title Description
FB9A Suspension of patent application procedure